- Home
- CVKD vs MNDO Comparison
CVKD vs MNDO Comparison
Compare CVKD & MNDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- MNDO
- Stock Information
- Founded
- CVKD 2022
- MNDO 1995
- Country
- CVKD United States
- MNDO Israel
- Employees
- CVKD N/A
- MNDO N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- MNDO EDP Services
- Sector
- CVKD Health Care
- MNDO Technology
- Exchange
- CVKD Nasdaq
- MNDO Nasdaq
- Market Cap
- CVKD 29.5M
- MNDO 26.5M
- IPO Year
- CVKD 2023
- MNDO 2000
- Fundamental
- Price
- CVKD $11.15
- MNDO $1.33
- Analyst Decision
- CVKD Strong Buy
- MNDO
- Analyst Count
- CVKD 1
- MNDO 0
- Target Price
- CVKD $32.00
- MNDO N/A
- AVG Volume (30 Days)
- CVKD 27.6K
- MNDO 30.0K
- Earning Date
- CVKD 08-19-2025
- MNDO 08-19-2025
- Dividend Yield
- CVKD N/A
- MNDO 16.54%
- EPS Growth
- CVKD N/A
- MNDO N/A
- EPS
- CVKD N/A
- MNDO 0.17
- Revenue
- CVKD N/A
- MNDO $20,677,000.00
- Revenue This Year
- CVKD N/A
- MNDO N/A
- Revenue Next Year
- CVKD N/A
- MNDO N/A
- P/E Ratio
- CVKD N/A
- MNDO $7.76
- Revenue Growth
- CVKD N/A
- MNDO N/A
- 52 Week Low
- CVKD $5.70
- MNDO $1.29
- 52 Week High
- CVKD $22.90
- MNDO $2.13
- Technical
- Relative Strength Index (RSI)
- CVKD 48.44
- MNDO 37.92
- Support Level
- CVKD $10.14
- MNDO $1.29
- Resistance Level
- CVKD $11.44
- MNDO $1.35
- Average True Range (ATR)
- CVKD 0.75
- MNDO 0.04
- MACD
- CVKD 0.07
- MNDO -0.01
- Stochastic Oscillator
- CVKD 74.38
- MNDO 19.05
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.